Pilot Study for a New Quasiorganelle Therapy in Dogs with Histiocytic Sarcoma

Histiocytic sarcoma is an aggressive cancer in dogs that often does not respond well to standard treatments like chemotherapy or radiation. While some dogs experience benefits, these treatments affect many cells at once and cannot adapt as a tumor changes. New research shows that cancer closely interacts with the immune system and surrounding tissues, suggesting that better treatments may need to work inside cells, not just target them from the outside. Quasiorganelle therapy is an experimental approach that aims to do this by using weakened, non-disease-causing bacteria derived from Listeria monocytogenes to deliver helpful genetic instructions directly into immune and tumor cells, with the goal of improving how the body recognizes and responds to cancer.

Michigan State University’s Veterinary Medical Center is recruiting dogs with histiocytic sarcoma for a funded pilot study evaluating a new experimental quasiorganelle therapy. Consider whether you have patients who may qualify and share this opportunity with appropriate clients. Study-related treatment, hospitalization, testing, and imaging are covered for enrolled dogs.  Download the flyer below or visit the VMC website to learn more about how to enroll a dog.